UCLH-6630 - LECANEMAB HOMECARE SERVICE

Description

The service requirements for the direct supply and administration of Lecanemab (Leqembi) in a patient's home, via a homecare delivery service. Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoE ε 4) heterozygotes or non-carriers. The service is being offered by UCLH private Healthcare and will be for private patients only. The requirement is for a private homecare provider situated in the UK to provide this service. Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk